A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension (MACiTEPH)

This study is prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 Study With open-label extension to evaluate Efficacy and safety of Macitentan 75 mg in Inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. The estimated enrolment is 230 patients and the total duration of the study is approximately 6 years. Start date July 7, 2020, estimated primary completion date May 14, 2024, estimated study completion date August 7, 2026

Learn more about MACiTEPH study on the clinicaltrials.gov website at this link

Scroll to Top